Mark Frohlich

Dr. Frohlich is a medical oncologist with deep drug development and translational research experience. From 2014-2017, Dr. Frohlich served as the Executive Vice President of Portfolio Strategy for Juno. Prior to that, he held various executive roles, including EVP R&D and Chief Medical Officer at Dendreon Corporation from 2005-2014 and VP and Medical Director for Xcyte Therapies from 2001-2005. Dr. Frohlich brings extensive expertise in immuno-oncology and cell therapy, experience with drug approvals in US and EU, and knowledge of reimbursement and commercialization challenges.